News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
About Mesothelioma
Latest News
- With a Tiny Bit of Cancer, Debate on How to Procee...
- The European Commission Grants Orphan Drug Designa...
- The efficacy and safety of weekly vinorelbine in r...
- Efficacy and Safety of Pemetrexed in Combination w...
- Malignant peritoneal mesothelioma as a rare cause ...
- Individual versus standard quality of life assessm...
- The value of occult disease in resection margin an...
- Trimodality treatment of malignant pleural mesothe...
- Video-assisted cervical thoracoscopy: a novel appr...
- Characterization of Human Mesothelioma Cell Lines ...
News Archives
- April 2007
- May 2007
- June 2007
- July 2007
- August 2007
- September 2007
- October 2007
- November 2007
- December 2007
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September 2008
- October 2008
- November 2008
- December 2008
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
- December 2009
- January 2010
- February 2010
- March 2010
Tuesday, June 10, 2008
Source: Mesothelioma Applied Research FoundationMerck has recently announced that its clinical trial of Vorinostat as second-line therapy for pleural mesothelioma patients who’ve failed the standard chemotherapy regimen for mesothelioma treatment has moved to Phase III status. Merck is now enrolling patients from cancer centers in the United States and the United Kingdom, as well as in Belgium, Germany, the Netherlands, New Zealand, Spain and Sweden.
Vorinostat, which is marketed as Zolinza, is an anticancer agent that has already won approval by the FDA for the treatment of cutaneous T-cell lymphoma, a type of Non-Hodgkin lymphoma that mainly affects the skin. Vorionstat’s use for the second-line treatment of mesothelioma is being studied in this randomized, double-blind trial, where its safety, tolerability and anti-tumor activity will be compared to a control group given only placebo, along with best supportive care. The primary endpoints of the trial include Vorionstat’s effects on overall survival, as well as an investigation regarding its safety and toxicity. The trial’s secondary endpoints will examine its overall response rate and any demonstration of progression-free survival, as well its effects on dyspnea and forced vital capacity.
The trial is mainly being conducted as an investigation of Vorionstat’s applicability as second-line therapy on patients who have failed the standard therapies of pemetrexed and cisplatin or carboplatin, but its use for patients who are not eligible for a pemetrexed-based protocol will also be investigated.
Labels: mesothelioma
posted by Belluck & Fox at 10:58 AM
